Dendrite Appoints Luke Beshar Chief Financial Officer; Committed to Achieving Aggressive Growth Goals.

Business & Medical Editors

MORRISTOWN, N.J.--(BUSINESS WIRE)--Jan. 22, 2002

Dendrite (NASDAQ/NMS: DRTE) today announced the appointment of Luke M. Beshar as Senior Vice President and Chief Financial Officer.

A former CFO of four companies, Mr. Beshar has more than 20 years of experience in financial and general management, as well as leading businesses through periods of rapid and dynamic change. He most recently served as Executive Vice President - Finance and Chief Financial Officer of Expanets, Inc., a 3,600-employee, Englewood, Colorado company that provides advanced voice and data communications solutions to businesses across the United States.

Mr. Beshar joins Dendrite during a period of unprecedented growth and development. In recent months, the company has:

- Secured $64 million in new business and added 6,000 new product users

- Signed a multi-year contract to serve Sanofi-Synthelabo Inc.'s 2,400+ member
U.S.-based field organization

- Announced new business with Pfizer in its Clinical Trial Services division;
launched strategic initiatives via Analytika division at five leading
pharmaceutical companies

- Formed an alliance with Oracle Corp. to develop an industry-specific customer
relationship management (CRM) system

- Continued to launch innovative new sales force automation (SFA) solutions

- Hired Paul Zaffaroni as President and COO and reorganized corporate structure
to increase operational efficiency and enhance service levels to clients

At Expanets (formerly based in Berkeley Heights, NJ), Mr. Beshar helped grow the company from start-up to $1.2 billion of revenue in three years. He helped acquire and integrate 27 businesses in just over two years, and launched a leasing joint venture with The CIT Group that achieved a $150 million run rate and profitability within nine months.

"Luke has a proven ability to deliver significant bottom-line results to growing companies such as Dendrite," said President and COO Paul Zaffaroni. "He brings us deep financial and management expertise in a broad array of industries. He's passionate about building businesses and developing people. His strong leadership will play an instrumental role in continuing our corporate momentum."

Mr. Beshar will replace CFO George Robson, who will remain with Dendrite as Executive Vice President to help execute an orderly transition and work with Chairman and CEO John Bailye on corporate strategy and development.

"I believe that Dendrite has all the building blocks in place--including a solid financial foundation, outstanding client base, strong executive team, and topnotch associates--to achieve its ambitious plans to grow revenues by over 20 percent annually over six years," said Mr. Beshar. "I am looking forward to working with the entire team. We will continue to provide focused revenue growth initiatives, relentless cost control, and world-class service to customers."

Prior to joining Expanets, Mr. Beshar served as Senior Vice President and CFO at PNY Technologies, Inc., a $350 million global manufacturer of personal computer memory modules. Earlier, he served as President, CEO, and CFO of WSR Corporation, a $225 million automobile aftermarket retailer and a portfolio company of Merrill Lynch Capital Partners. Previously, he was Vice President and CFO of the Genlyte Group, a $430 million public company and manufacturer of lighting fixtures in North America.

Mr. Beshar began his career with Arthur Andersen & Co. He is a Certified Public Accountant and a graduate of The Executive Program from the Darden Graduate School of Business, University of Virginia. He received a B.A. in Accounting from Michigan State University. He currently resides in Summit, New Jersey with his wife and two children.

About Dendrite

Dendrite, the visionary innovator in global pharmaceutical technology, helps clients strategically manage customer relationships to increase market share. The company creates unique, analytically driven solutions that enable pharmaceutical companies to influence prescriber behavior, thereby delivering a sustained competitive advantage. More than 80,000 pharmaceutical sales representatives and their managers from over 150 companies and 57 countries use Dendrite products and services. They represent 19 of the top 20 pharmaceutical companies. For more information, visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The statements may be identified by such forward-looking terminology as "expect," "believe," "may," "will," "intend," "plan," and similar statements or variations. Such forward-looking statements are based on our current estimates and assumptions and involve certain significant risks and uncertainties, including: risks associated with and dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy selling cycles, product implementation cycles, customer budget cycles, and timing of revenue recognition; dependence on major customers; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; retention of key senior managers; and unique characteristics of the consumer packaged goods industry. Other important factors that should be considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements.